FIELD: biotechnology.
SUBSTANCE: disclosed are bispecific antibodies specifically binding to PD-1 and CD19. Bispecific antibodies have the property of providing interaction between PD-1 and PD-L1 as their ligand. Also disclosed are pharmaceutical compositions containing said antibodies.
EFFECT: said antibodies are novel agents for preventing, suppressing progression of symptoms or relapse, or treating autoimmune diseases.
36 cl, 22 dwg, 22 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODY | 2019 |
|
RU2796019C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| MULTI-SPECIFIC ANTIBODIES AND METHODS OF THEIR PRODUCTION AND USE | 2018 |
|
RU2811477C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND THEIR USE | 2018 |
|
RU2780020C2 |
| LY6G6D ANTIBODIES AND METHODS OF USE | 2020 |
|
RU2818569C1 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
